Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics Inc (NQ: KYMR )

28.90 +0.73 (+2.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 371,545
Open 28.70
Bid (Size) 28.83 (4)
Ask (Size) 28.91 (72)
Prev. Close 28.17
Today's Range 27.95 - 29.63
52wk Range 13.15 - 44.74
Shares Outstanding 55,183,644
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
+16.34%
+16.34%
1 Month
-5.92%
-5.92%
3 Month
+5.01%
+5.01%
6 Month
+23.03%
+23.03%
1 Year
-32.48%
-32.48%

More News

Read More
Kymera Therapeutics's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Kymera Therapeutics
Via Benzinga
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via Globe NewsWire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
From Kymera Therapeutics, Inc.
Via Globe NewsWire
X-Chem and Kymera Expand Existing Partnership
From X-Chem
Via Business Wire
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
From Kymera Therapeutics, Inc.
Via Globe NewsWire
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
From Kymera Therapeutics, Inc.
Via Globe NewsWire
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Kymera Therapeutics, Inc.
Via Globe NewsWire
7 Perfect Presents to Gift Your 2023 Stock Portfolio
Via InvestorPlace
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Via The Motley Fool
Dear DS Stock Fans, Mark Your Calendars for Dec. 23
Via InvestorPlace
Why Is SOFI Stock Up 7% Today?
Via InvestorPlace
Dear CRKN Stock Fans, Mark Your Calendars for Dec. 22
Via InvestorPlace
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
Via InvestorPlace
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial
Via Benzinga
US Stocks Higher Ahead Of Fed Decision
Via Benzinga
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
From Kymera Therapeutics, Inc.
Via Globe NewsWire
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.